RxDoctor Payments Data

Husam Nazer, MD

Gastroenterology · Beckley, WVNPI 1811178106

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Pfizer at 27.5% of the total. Reporting peaked in 2023 at $452 and has fallen 73.8% since, to $119 in 2025. That places this record below the midpoint for gastroenterology clinicians in WV, where the typical reported total is $1,371.

$1,133in general payments, 2019–2025

Across 49 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$312
  • AbbVie$274
  • Takeda Pharmaceuticals U.S.A., Inc.$197
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$98
  • Merck$49
  • AstraZeneca$25
  • plus $178 from 9 others

What the payments were for

  • Food & beverage$1,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,133 in reported general payments places this provider in the 40th percentile of 72 gastroenterology providers in West Virginia.

See all gastroenterology providers in West Virginia

Medicare billing

Part B allowed, 2024
$70,222
Medicare patients
306
Services billed
792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$387,357
LinzessLinaclotide83$55,343
XifaxanRifaximin14$46,690
Mesalamine ErMesalamine29$7,271
MotegrityPrucalopride Succinate14$7,029
Sucralfate155$4,293
Pantoprazole Sodium443$3,757
Famotidine329$2,558
Lactulose86$2,329
Lubiprostone21$2,235
Omeprazole270$2,212
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,675
Dicyclomine Hcl81$1,577
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl68$1,119
Esomeprazole Magnesium37$972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$274$55,34383 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$98$46,69014 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$197$7,02914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 72 gastroenterology providers in West Virginia.

Other gastroenterology in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →